New DNA Discovery Links SLAMF1 Gene to Canine Atopic Dermatitis in French Bulldogs and Boxers
A new study published in Frontiers in Veterinary Science has identified a specific genetic variant associated with canine atopic dermatitis (cAD) — a common, painful skin condition affecting up to 30% of dogs. The research, led by scientists from Wisdom Panel™, establishes a link between the SLAMF1 gene and increased risk of cAD in French Bulldogs and Boxers, breeds already overrepresented in veterinary dermatology clinics.
The variant was detected in 71% of French Bulldogs and 40% of Boxers tested, indicating a significant predisposition in these breeds. The study analyzed clinical data from Banfield® Pet Hospital alongside genomic information from Wisdom Panel, marking one of the first times such a link has been established in canine dermatological research.
Genetic Insight, Real-World Implications
Canine atopic dermatitis is a lifelong condition with no known cure. It causes severe itching, inflammation, and skin infections that significantly reduce quality of life. Until now, treatment has focused on symptom management without the ability to address the genetic roots.
This research confirms the heritable nature of the disease and supports future development of:
Genetic screening tools
Informed breeding decisions
Breed-specific prevention strategies
New avenues for therapeutic development
Although French Bulldogs and Boxers were the focus, scientists believe the SLAMF1 variant may play a role in other breeds and warrant further investigation.
Backed by Veterinary and Genomic Collaboration
The study involved a multidisciplinary collaboration across Mars Petcare’s global ecosystem, including:
Wisdom Panel (genetic testing and analysis)
Banfield Pet Hospital (clinical data)
MARS PETCARE BIOBANK™ (sample validation)
Expert veterinary dermatologists from Linnaeus
Genetic testing support from the University of Cambridge’s Department of Veterinary Medicine
The result is a functional genetic test, now available through Wisdom Panel in partnership with Canine Genetic Testing, designed to help breeders make data-driven decisions to reduce the frequency of atopic dermatitis without compromising genetic diversity.
Why It Matters for Veterinarians
Veterinarians treating dermatologic cases in these breeds now have access to genetic risk data that can be factored into:
Early diagnostics
Preventive care
Client education
Long-term disease management plans
This discovery underscores the value of integrating genomics into general practice — not only for breeding purposes, but also to improve quality of life through precision medicine.
FAQs: SLAMF1 and Canine Atopic Dermatitis
What is canine atopic dermatitis (cAD)?
It’s a chronic inflammatory skin disease caused by environmental allergens. It typically presents with severe itching, hair loss, and skin infections. There is no cure, but symptoms can be managed.
What breeds are most affected?
French Bulldogs and Boxers are highly represented in dermatology clinics and now genetically confirmed to be at increased risk due to the SLAMF1 gene variant.
What does SLAMF1 do?
SLAMF1 is involved in immune system signaling. Variants in the gene are thought to contribute to abnormal immune responses in the skin.
Is there a test for this genetic variant?
Yes. Wisdom Panel, in collaboration with the University of Cambridge, now offers a DNA test for breeders and veterinarians to identify dogs carrying the SLAMF1 variant.
How can veterinarians use this information?
Vets can use this data to counsel breeders and pet owners on genetic risk, promote early detection, and potentially adjust management strategies for at-risk dogs.
